The ASCO Post Staff
/
Friday, October 25, 2024 5:25 PM
The ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a new multiyear research collaboration that will begin with the interrogation of the TAILORx trial.
Background
Breast cancer remains the most common cancer type in the United States, with approximately 310,720 new cases per...
Jo Cavallo
/
Monday, October 28, 2024 11:55 AM
In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....
Jo Cavallo
/
Monday, October 28, 2024 12:55 PM
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Matthew Stenger
/
Monday, October 28, 2024 11:00 AM
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer.
Study Details
In the open-label trial,...
The ASCO Post Staff
/
Monday, October 28, 2024 11:11 AM
Researchers have demonstrated that anti–PD-L1 immunotherapy combined with mutation-directed targeted therapy may improve overall survival in patients with anaplastic thyroid carcinoma, according to a recent study published by Cabanillas et al in JAMA Oncology.
Background
Anaplastic thyroid...
The ASCO Post Staff
/
Thursday, October 24, 2024 2:43 PM
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting.
Background
Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
Matthew Stenger
/
Thursday, October 24, 2024 1:30 PM
As reported in The New England Journal of Medicine by van As et al, the phase III PACE-B trial has shown noninferiority of stereotactic body radiotherapy (SBRT) vs conventionally fractionated radiotherapy in biochemical or clinical failure in patients with low- to intermediate-risk localized...
The ASCO Post Staff
/
Thursday, October 24, 2024 2:46 PM
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
Matthew Stenger
/
Thursday, October 24, 2024 12:57 PM
In a study reported in the Journal of Clinical Oncology, Phillips et al found that carriers of BRCA1—but not BRCA2—germline mutations who used hormonal contraception were at increased risk for developing breast cancer.
Study Details
The investigators used pooled data from four prospective cohort...
Caroline Helwick
/
Wednesday, October 23, 2024 12:15 PM
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes.1
...
Matthew Stenger
/
Wednesday, October 23, 2024 11:07 AM
In a Dutch study reported in the Journal of Clinical Oncology, Westerveld et al identified long-term risks of subsequent neoplasms in 5-year survivors of childhood neuroblastoma.
Study Details
The study included data from 563 survivors in the Dutch Childhood Cancer Survivor Study–LATER cohort...
Matthew Stenger
/
Wednesday, October 23, 2024 10:51 AM
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC).
Study Details
In the multicenter trial, 46...
The ASCO Post Staff
/
Wednesday, October 23, 2024 10:26 AM
The University of Arizona Health Sciences announced that it has received a $3.3 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to continue testing a novel imaging method for breast cancer detection that could provide an alternative to the mammogram.
...
The ASCO Post Staff
/
Wednesday, October 23, 2024 10:21 AM
Magnetic resonance imaging (MRI) may help patients with rectal cancer avoid invasive surgery and its potentially lifelong side effects, according to a recent study published by Williams et al in Radiology.
Background
“After undergoing chemotherapy and radiation for rectal cancer, patients are...
Chase Doyle
/
Wednesday, October 23, 2024 11:00 AM
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
The ASCO Post Staff
/
Monday, September 23, 2024 12:50 PM
The Affordable Care Act (ACA) has increased guideline-concordant care for colorectal cancer among non-White patients, those from rural areas, and those from the most deprived neighborhoods in Pennsylvania, according to new findings presented by Kudaravalli et al at the 2024 American Association for ...
The ASCO Post Staff
/
Tuesday, October 22, 2024 11:20 AM
Listening to music may accelerate postsurgical recovery, according to recent findings presented by Raees et al at the American College of Surgeons (ACS) Clinical Congress 2024.
Background
“When patients wake up after surgery, sometimes they feel really scared and don’t know where they are,”...
Matthew Stenger
/
Tuesday, October 22, 2024 12:58 PM
In the Canadian phase II OPAR trial reported in the Journal of Clinical Oncology, Kim et al found no difference in adverse cosmesis with partial breast irradiation (PBI) in five daily fractions of 30 Gy vs 27.5 Gy given over 1 week in patients with early breast cancer. The aim of the trial was to...
Matthew Stenger
/
Tuesday, October 22, 2024 1:07 PM
In an analysis of two clinical trials reported in the Journal of Clinical Oncology, Weber et al identified “cure rates” with adjuvant nivolumab, ipilimumab, and placebo in patients with resected stage III/IV melanoma.
Study Details
The analysis used mixture cure models (MCMs) to estimate cure...
The ASCO Post Staff
/
Tuesday, October 22, 2024 11:26 AM
Investigators have highlighted a critical connection between heart failure and cancer, demonstrating how shared mechanisms may contribute to the incidence and progression of both diseases, according to a recent scientific statement published by Bloom et al in the Journal of Cardiac Failure.
...
Julia Cipriano, MS
/
Tuesday, October 22, 2024 12:30 PM
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Caroline Helwick
/
Tuesday, October 22, 2024 11:05 AM
An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...
The ASCO Post Staff
/
Monday, October 21, 2024 11:17 AM
On October 18, Gilead Sciences announced its plans to voluntarily withdraw the U.S. accelerated approval for sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing...
The ASCO Post Staff
/
Monday, October 21, 2024 12:53 PM
Researchers have found that financial fallout can follow patients with cancer and their families as financial bankruptcy, lower credit scores, and other types of financial challenges in the years following a cancer diagnosis, according to two new studies presented by Gomez-Mayorga et al and
Matthew Stenger
/
Monday, October 21, 2024 1:06 PM
In the phase Ib FORT-2 trial reported in JAMA Oncology, Sweis et al found that the combination of the pan-FGFR inhibitor rogaratinib and atezolizumab was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer overexpressing FGFR mRNA.
Study Details
The study ...
The ASCO Post Staff
/
Monday, October 21, 2024 12:58 PM
Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification program may reduce rates of postsurgical mortality and increase the proportion of patients with documentation standards such as advanced care directives, according to two new studies presented by Horattas et al and
Matthew Stenger
/
Monday, October 21, 2024 12:48 PM
As reported in the Journal of Clinical Oncology by Pavlakis et al, the phase III INTEGRATE IIa study showed improved overall survival with regorafenib plus best supportive care vs placebo vs best supportive care in patients with refractory advanced gastric/esophagogastric junction cancer.
Study...
The ASCO Post Staff
/
Friday, October 18, 2024 2:39 PM
The U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal ...
The ASCO Post Staff
/
Friday, October 18, 2024 11:46 AM
Younger adults with colon cancer tend to be diagnosed at a later stage and have more aggressive types of tumors. Additionally, young patients living with colorectal cancer have long-term, adverse consequences on their lives, which are different from the impact the disease has on older adults,...
Jo Cavallo
/
Friday, October 18, 2024 1:22 PM
Although improving cancer screening participation in the United States is central to the country’s national goals for reducing disability and death, currently, participation is lagging behind the Healthy People 2030 targets set by the U.S. Department of Health and Human Services.
A study by the...
Matthew Stenger
/
Friday, October 18, 2024 11:58 AM
In a study reported in a research letter in JAMA Network Open, Rezaei et al found that risk of melanoma and other nonkeratinocyte skin cancers was elevated in patients who had received radioactive iodine treatment for thyroid cancer.
Study Details
The study involved data from 17 Surveillance,...
The ASCO Post Staff
/
Friday, October 18, 2024 11:33 AM
The Society of Thoracic Surgeons (STS) announced the introduction of two new risk calculators to inform physician-patient decision-making in thoracic surgery.
Engineered using contemporary data from the STS General Thoracic Surgery Database, the interactive tools may provide surgeons with...
The ASCO Post Staff
/
Friday, October 18, 2024 11:27 AM
Investigators have found that about 40% of postmenopausal hormone receptor–positive breast cancer cases may be linked to excess body fat, according to a recent study published by Cubelos-Fernández et al in the Journal of Epidemiology & Community Health.
Background
Using the widely used...
The ASCO Post Staff
/
Thursday, October 17, 2024 12:22 PM
Investigators have found that one-third of adult survivors of childhood cancers may experience a severe fear of cancer recurrence that impacts their daily lives, according to a recent study published by Pizzo et al in JAMA Network Open.
Background
Although the number of survivors of childhood...
The ASCO Post Staff
/
Thursday, October 17, 2024 12:17 PM
Researchers have found that the combination of nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) may reduce the risk of cancer progression and mortality in patients with Hodgkin lymphoma compared with standard treatment, according to a recent study published by Herrera et al in The New ...
Matthew Stenger
/
Thursday, October 17, 2024 12:14 PM
As reported in the Journal of Clinical Oncology by Werr et al, high telomerase reverse transcriptase (TERT) expression has been found to be associated with poorer survival in patients with pulmonary carcinoids.
As stated by the investigators: “The clinical course of pulmonary carcinoids ranges...
Matthew Stenger
/
Thursday, October 17, 2024 12:06 PM
In a Chinese phase III trial (Northern Radiation Oncology Group of China-002) reported in the Journal of Clinical Oncology, Sun et al found that the addition of thoracic radiotherapy to EGFR tyrosine kinase inhibitor (TKI) treatment improved progression-free survival in first-line treatment of...
Susan Reckling, MA
/
Thursday, October 17, 2024 11:45 AM
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
The ASCO Post Staff
/
Wednesday, October 16, 2024 12:48 PM
Yesterday, Novocure announced the U.S. Food and Drug Administration (FDA) approval of Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) who have experienced disease progression on or after a...
Matthew Stenger
/
Wednesday, October 16, 2024 12:29 PM
In an interim analysis of the phase II RAMOSE trial, reported in the Jour�nal of Clinical Oncology, Le et al found that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival as initial treatment in patients with tyrosine kinase inhibitor (TKI)-naive...
Matthew Stenger
/
Wednesday, October 16, 2024 12:23 PM
As reported in The New England Journal of Medicine by Lerner et al, the phase III SWOG S1011 trial showed no disease-free survival benefit for extended vs standard lymphadenectomy in patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Study Details
In the trial, 592...
The ASCO Post Staff
/
Wednesday, October 16, 2024 11:46 AM
Many patients with head and neck cancer may lack equal opportunity to access experimental treatments in clinical trials or receive treatments that were shown to be effective in similar patients, according to a recent study published by Zuckerman and Edwards in Head & Neck.
Background
Millions ...
Julia Cipriano, MS
/
Wednesday, September 18, 2024 12:15 PM
The second planned interim analysis of the global phase III AEGEAN trial—reported by John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer...
The ASCO Post Staff
/
Tuesday, October 15, 2024 12:48 PM
Millions of U.S. patients with cancer may face barriers to accessing some of the most advanced treatments being tested in clinical trials for their disease, according to a recent study published by Kirkwood et al in JCO Oncology Practice.
Background
“We need to support bringing clinical trials to ...
The ASCO Post Staff
/
Tuesday, October 15, 2024 12:43 PM
Some cancer types may be slightly more prevalent among patients with multiple sclerosis compared with those without the condition, according to a recent study published by Pierret et al in Neurology.
Background
In multiple sclerosis, the body’s immune system attacks myelin, the fatty white...
Matthew Stenger
/
Tuesday, October 15, 2024 11:27 AM
As reported in The Lancet Oncology by Wolf et al, the final results of the phase II GEOMETRY mono-1 trial support the activity of the kinase inhibitor capmatinib in patients with non–small cell lung cancer (NSCLC) with MET exon 14–skipping mutation (METex14).
Study Details
The multicohort trial ...
Matthew Stenger
/
Tuesday, October 15, 2024 11:21 AM
In a study reported in JAMA Network Open, Bodelon et al found that survivors of first primary cancers with overweight or obesity were at increased risk for second primary cancers, particularly obesity-related cancers.
Study Details
The study focused on data from the Cancer Prevention Study II...
Matthew Stenger
/
Monday, October 14, 2024 12:20 PM
Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic resonance imaging (MRI) results eliminated a high proportion of diagnoses of clinically insignificant...
Matthew Stenger
/
Monday, October 14, 2024 11:57 AM
In a study published as a research letter in JAMA Oncology, Cederquist et al found that patients with breast cancer who received adjuvant radiation therapy and harbored likely pathogenic TP53 germline variants were at increased risk of developing secondary in-field sarcoma during follow-up.
Study...
The ASCO Post Staff
/
Monday, October 14, 2024 11:46 AM
Researchers have identified genetic risk factors that may contribute to prostate cancer in a diverse group of African men, according to a recent study published by Janivara et al in Nature Genetics. The findings could uncover new treatment options in this patient population.
Background
Certain...
The ASCO Post Staff
/
Monday, October 14, 2024 11:41 AM
Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing.
...
The ASCO Post Staff
/
Friday, October 11, 2024 11:09 AM
The U.S. Food and Drug Administration (FDA) approved the PI3K inhibitor inavolisib (Itovebi) with the CDK4/6 inhibitor palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, as...
Matthew Stenger
/
Friday, October 11, 2024 11:42 AM
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma.
Study Details
In the multicenter trial, 37 evaluable patients with...
The ASCO Post Staff
/
Friday, October 11, 2024 11:08 AM
Despite considerable progress in the discovery and development of new cancer drugs between 1990 and 2022, there may be disparities in both the availability and timeliness of these treatment options globally, particularly among lower-income countries, according to a recent study published by Li et...
The ASCO Post Staff
/
Friday, October 11, 2024 11:02 AM
Researchers at Case Western Reserve University and Vanderbilt University have received a $3.7 million grant from the National Cancer Institute to pioneer a novel approach to prostate cancer surgery that combines advanced robotics and low-field magnetic resonance imaging (MRI) technology.
Overview...
The ASCO Post Staff
/
Monday, October 7, 2024 1:02 PM
The American Society for Health-System Pharmacists (ASHP) and the University of Utah announced updated recommendations for managing intravenous fluid shortages and conserving supply after Hurricane Helene forced the closure of a critical manufacturing plant in North Carolina.
The management and...
The ASCO Post Staff
/
Wednesday, October 9, 2024 10:58 AM
Canadian vaccination programs may switch to a one-dose, gender-neutral human papillomavirus (HPV) vaccination approach to eliminate cervical cancer, according to a recent study published by Drolet et al in the Canadian Medical Association Journal.
Background
HPV is known to cause cervical cancer...
The ASCO Post Staff
/
Wednesday, October 9, 2024 1:00 AM
A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...
The ASCO Post Staff
/
Wednesday, October 9, 2024 1:00 AM
In a Journal of Clinical Oncology editorial, Yara Abdou, MD, and Norman E. Sharpless, MD, responded to a recent study by the Fred Hutchinson Cancer Center in Seattle that found enrollment in industry-sponsored cancer clinical trials doubled between 2008 and 2022, whereas federally supported trial ...
Matthew Stenger
/
Tuesday, October 8, 2024 11:07 PM
As reported in JAMA Oncology by Swaminath et al, the Canadian phase III LUSTRE trial has shown no significant benefit in local tumor control with stereotactic body radiotherapy (SBRT) vs hypofractionated conventional radiotherapy (CRT) in patients with inoperable stage I non–small cell lung cancer...
The ASCO Post Staff
/
Tuesday, October 8, 2024 10:52 PM
A recent study suggests that for people older than age 65 who have cancer, physical activity may be key to reducing the chances of a dangerous fall. People with lung cancer, colorectal cancer, or prostate cancer, in particular, had a lower risk of falling when they talked with their doctor...
The ASCO Post Staff
/
Wednesday, October 9, 2024 10:54 AM
A novel cell therapy targeting CD7 on leukemia cells may provide an effective treatment option for patients with refractory T-cell acute lymphoblastic leukemia (ALL), according to a recent study published by Oh et al in Nature Medicine. The findings highlighted the effectiveness of a new chimeric...
Matthew Stenger
/
Wednesday, October 9, 2024 1:53 PM
In the PREVENT trial, reported as a research letter in JAMA Oncology, Hu et al found that transperineal prostate biopsy resulted in less risk of infection than transrectal biopsy in patients with suspicion of prostate cancer, with no difference between methods observed in detecting high-grade...
Matthew Stenger
/
Tuesday, October 8, 2024 1:50 PM
In an analysis from the phase III SHAPE trial reported in the Journal of Clinical Oncology, Ferguson et al found that simple hysterectomy was associated with a reduced risk of sexual dysfunction vs radical hysterectomy in patients with low-risk, early-stage cervical cancer. The trial showed...
The ASCO Post Staff
/
Tuesday, October 8, 2024 11:59 AM
Researchers have found that common breast cancer treatments—including chemotherapy, radiation, and surgery—may accelerate the biological aging process among breast cancer survivors, according to a new study published by Carroll et al in the Journal of the National Cancer Institute. The findings...
The ASCO Post Staff
/
Tuesday, October 8, 2024 11:56 AM
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer.
The federal...
Matthew Stenger
/
Tuesday, October 8, 2024 11:45 AM
In the European TransMet trial, reported in The Lancet, Adam et al found that liver transplantation plus chemotherapy improved overall survival vs chemotherapy alone in patients with permanently unresectable colorectal cancer liver metastases.
Study Details
In the open-label trial, 94 patients...
The ASCO Post Staff
/
Monday, October 7, 2024 2:05 PM
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly...
The ASCO Post Staff
/
Thursday, October 3, 2024 1:21 PM
A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in
The ASCO Post Staff
/
Friday, October 4, 2024 12:02 PM
A radiopharmaceutical therapy has demonstrated early efficacy in patients with difficult-to-treat meningioma, according to new findings presented by Merrell et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 2) and simultaneously published in the
The ASCO Post Staff
/
Monday, October 7, 2024 11:12 AM
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics.
Background
According to recent surveys, physicians may spend almost 3 hours per day on documentation activities.
“The...
The ASCO Post Staff
/
Monday, October 7, 2024 11:05 AM
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
The ASCO Post Staff
/
Friday, October 4, 2024 12:06 PM
Spiritual beliefs and a historically based distrust of clinical research may influence Black patients’ decisions about whether to participate in cancer trials, according to new findings presented by Gomez et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract...
Matthew Stenger
/
Friday, October 4, 2024 1:06 PM
As reported in Journal of Clinical Oncology by Gyurkocza et al, the phase III SIERRA trial has shown higher rates of durable complete remissions with the anti-CD45 radioconjugate iodine-131–apamistamab vs conventional care followed by allogeneic hematopoietic cell transplantation (allo-HCT) in...
Matthew Stenger
/
Friday, October 4, 2024 12:46 PM
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...
Matthew Stenger
/
Thursday, October 3, 2024 12:06 PM
In an analysis reported in the Journal of Clinical Oncology, Tournilhac et al identified 7-year outcomes of the phase III AATT trial evaluating autologous vs allogeneic transplantation in younger patients with peripheral T-cell lymphoma.
Study Details
In the trial, 103 patients (aged 18–60) from...
The ASCO Post Staff
/
Thursday, October 3, 2024 11:56 AM
A substantial number of patients with brain metastases who experience cognitive side effects after radiation therapy may fully regain cognitive function, according to recent findings presented by Cherng et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 150). ...
Steven Clark Cunningham, MD, MLA, FACS, and Gwynn Ison, MD
/
Thursday, October 3, 2024 11:45 PM
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers...
The ASCO Post Staff
/
Thursday, October 3, 2024 11:46 AM
An accelerated course of postmastectomy radiation therapy may not increase complications in patients with breast cancer undergoing breast reconstruction, according to recent findings presented by Poppe et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1) and ...
Matthew Stenger
/
Thursday, October 3, 2024 11:18 AM
As reported in the Journal of Clinical Oncology by Motzer et al, part B of the phase III CheckMate 914 trial showed no disease-free survival benefit with the adjuvant use of nivolumab vs placebo in patients with localized renal cell carcinoma at high risk of recurrence after nephrectomy. These...
The ASCO Post Staff
/
Wednesday, October 2, 2024 11:42 AM
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
The ASCO Post Staff
/
Wednesday, October 2, 2024 11:34 AM
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...
Matthew Stenger
/
Wednesday, October 2, 2024 11:55 AM
As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial has shown that immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib did not improve progression-free survival vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint...
Matthew Stenger
/
Wednesday, October 2, 2024 12:47 PM
As reported in the Journal of Clinical Oncology by Nichols et al, final results of the phase II ORATOR trial indicate some differences in toxicity and quality of life between radiotherapy and transoral robotic surgery for oropharyngeal squamous cell carcinoma, with both approaches yielding similar...
Matthew Stenger
/
Wednesday, October 2, 2024 12:36 PM
As reported in The Lancet by Morris et al, the phase III PSMAfore trial has shown improved progression-free survival with lutetium-177–labeled PSMA-617 (LuPSMA) vs change in androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with metastatic castration-resistant prostate cancer...
The ASCO Post Staff
/
Tuesday, October 1, 2024 2:56 PM
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
Matthew Stenger
/
Tuesday, October 1, 2024 1:37 PM
As reported in The Lancet by Spicer et al, overall survival results of the phase III KEYNOTE-671 trial indicate benefit of the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab in patients with early-stage non–small cell lung cancer (NSCLC).
At the first...
Chase Doyle
/
Tuesday, October 1, 2024 1:30 PM
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast ...
Julia Cipriano, MS
/
Tuesday, October 1, 2024 1:20 PM
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
The ASCO Post Staff
/
Tuesday, October 1, 2024 11:21 AM
Investigators have uncovered a higher risk for strokes, heart attacks, and hospital admissions for heart failure in older cancer survivors, according to a recent study published by Muhandiramge et al in Cancer.
Background
Although advances in cancer treatment have led to decreased mortality rates ...
The ASCO Post Staff
/
Tuesday, October 1, 2024 11:16 AM
Investigators have identified a substantial increase in the proportion of U.S. patients with cancer participating in clinical trials sponsored by the pharmaceutical industry over the past decade compared with those supported by the federal government, according to findings recently presented by...
Matthew Stenger
/
Monday, September 30, 2024 12:49 PM
As reported in The Lancet Oncology by Iliopoulos et al, updated findings from the phase II LITESPARK-004 trial support the efficacy of belzutifan in patients with von Hippel-Lindau (VHL) disease–associated CNS hemangioblastomas.
Study Details
In the study, 50 patients with CNS hemangioblastomas...
Matthew Stenger
/
Monday, September 30, 2024 11:25 AM
In a retrospective analysis from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG) reported in the Journal of Clinical Oncology, Luo et al found that whole-lung irradiation (WLI) was associated with significantly better event-free survival vs no WLI in patients with newly...
The ASCO Post Staff
/
Monday, September 30, 2024 11:15 AM
Advancing surgical and pathologic techniques may improve overall survival rates in high-risk patients with lung cancer, according to new findings presented by Akinbobola et al at the 2024 ASCO Quality Care Symposium (Abstract 278).
Background
“Over the past 15 years, a quality improvement...
The ASCO Post Staff
/
Monday, September 30, 2024 11:11 AM
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224).
Background
...
Jo Cavallo
/
Tuesday, September 24, 2024 1:45 PM
The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level, impacting payer costs and patient cost-sharing amounts,...
The ASCO Post Staff
/
Friday, September 27, 2024 4:43 PM
On September 27, 2024, the U.S. Food and Drug Administration granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require...
The ASCO Post Staff
/
Friday, September 27, 2024 11:35 AM
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
Matthew Stenger
/
Friday, September 27, 2024 10:50 AM
As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with...
The ASCO Post Staff
/
Friday, September 27, 2024 11:29 AM
Researchers have found that olanzapine may be more effective in controlling severe nausea and improving the quality of life in patients with cancer who are undergoing treatment with chemotherapy, according to new findings presented by Peppone et al at the 2024 ASCO Quality Care Symposium (Abstract...